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Background: HOX gene expression is altered in many cancers; previous microarray revealed changes in HOX gene expression in
head and neck squamous cell carcinoma (HNSCC), particularly HOXD10.
Methods: HOXD10 expression was assessed by qPCR and immunoblotting in vitro and by immunohistochemistry (IHC) in tissues.
Low-expressing cells were stably transfected with HOXD10 and the phenotype assessed with MTS, migration and adhesion assays
and compared with the effects of siRNA knockdown in high-HOXD10-expressing cells. Novel HOXD10 targets were identified
using expression microarrays, confirmed by reporter assay, and validated in tissues using IHC.
Results: HOXD10 expression was low in NOKs, high in most primary tumour cells, and low in lymph node metastasis cells, a
pattern confirmed using IHC in tissues. Overexpression of HOXD10 decreased cell invasion but increased proliferation, adhesion
and migration, with knockdown causing reciprocal effects. There was no consistent effect on apoptosis. Microarray analysis
identified several putative HOXD10-responsive genes, including angiomotin (AMOT-p80) and miR-146a. These were confirmed as
HOXD10 targets by reporter assay. Manipulation of AMOT-p80 expression resulted in phenotypic changes similar to those on
manipulation of HOXD10 expression.
Conclusions: HOXD10 expression varies by stage of disease and produces differential effects: high expression giving cancer cells
a proliferative and migratory advantage, and low expression may support invasion/metastasis, in part, by modulating AMOT-p80
levels.
Alterations in the genome and transcriptome of head and neck
squamous cell carcinoma (HNSCC) are variable and related to the
cancer site and stage. This heterogeneity has hindered the
identification of molecular alterations that could be exploited as
therapeutic targets in HNSCC. The prognosis for patients with
HNSCC remains poor for the majority of patients who present at
an advanced stage of disease (Leemans et al, 2011). Recent
advances in the genomic characterisation of HNSCC have
identified a number of potential somatic drivers, including
NOTCH; however, these are not ubiquitous and subclassification
of HNSCC will be required as further detail emerges (Agrawal et al,
2011; Pickering et al, 2013). It is not yet known whether alterations
in these newly identified oncogenic drivers are related to disease
severity or clinical outcome in HNSCC.
Our previous transcriptomic analysis of cell cultures from all
stages of HNSCC development identified consistent alterations
including dysregulation of expression of a number of HOX genes
(Hunter et al, 2006), one of which was HOXD10. HOX genes form
a large group of 39 homeodomain-containing transcription factors,
found within four clusters in the genome (A, B, C and D), which
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are involved in embryonic development and also have a role in
stem cell function (Picchi et al, 2013). Alterations in expression of
HOX genes have been identified in a number of cancers, including
haematolymphoid/leukaemias, breast and lung cancer (Abe et al,
2006; Rice and Licht, 2007; Gilbert et al, 2010).
Given their wide range of functions, it is not surprising that
HOX genes may be either silenced or overexpressed in cancer. The
effects of this aberrant expression in tumour cells include
alterations in differentiation, apoptosis and receptor signalling
pathways, and have been associated with control of EMT and
promotion or inhibition of invasion (Wu et al, 2006; Wardwell-
Ozgo et al, 2014). Control of expression is complex and, for many
HOX genes, has not been fully elucidated; however, epigenetic
control and the action of microRNAs and other non-coding RNAs,
such as HOTAIR, have been demonstrated (Rinn et al, 2007).
Furthermore, the similarity in function between the paralogous
groups of HOX genes introduces an element of functional
redundancy, yet it is clear that the functions are not completely
interchangeable between paralogues (Eklund, 2007). This indicates
that, whereas HOX genes present potential therapeutic targets,
significant challenges remain. Nevertheless, a number of small
molecular inhibitors of the interaction between HOX genes and
their cofactor PBX have been developed, including HXR9 (Morgan
et al, 2012). Identification of consistent changes in specific HOX
genes in particular cancers may present novel therapeutic targets or
prognostic markers that can be exploited to improve clinical
outcomes.
As the preliminary array data suggested increased expression of
HOXD10 in SCC cells when compared with normal keratinocytes,
this study aimed to validate this observation and understand the
role high HOXD10 expression may have in HNSCC development.
MATERIALS AND METHODS
Cell Culture. Head and neck squamous cell carcinoma cell
lines, oral pre-malignant (OPL), primary normal oral keratino-
cytes (NOKs) and immortalised normal oral keratinocytes
(Supplementary Table S3) were maintained in KGM (DMEM
supplemented with 23% Ham’s F-12, 10% FCS, L-glutamine
(2mM), adenine (0.18mM), hydrocortisone (0.5 mgml 1) and
insulin (5 mgml 1; Sigma Aldrich, Cambridge, UK) at 37 1C and
5% CO2. Primary NOKs were isolated as previously described
(Hearnden et al, 2009).
RNA extraction and qPCR. Total RNA was extracted using the
ISOLATE RNA mini kit (Bioline Reagents Ltd, London, UK)
before quantification and purity assessment (A260/280X1.9) using
NanoDrop Spectrophotometer (Fisher Scientific, Loughborough,
UK). cDNA was generated using the High Capacity cDNA Reverse
Transcription kit (Life Technologies, Paisley, UK) with random
primers or miR-specific stem–loop primers (Life Technologies).
TaqMan probes and primers (Life Technologies) or primers for
SYBR green chemistry (Sigma AldrichSupplementary Table S3)
were used to amplify target sequences using qPCR (7900HT
thermocycler, Life Technologies). Data were analysed using the RQ
Manager 1.2.1 software (Life Technologies).
Antibodies. Antibodies used were goat polyclonal anti-HOXD10
(Santa Cruz Biotechnology, Dallas, TX, USA), rabbit polyclonal
anti-HOXD10, rabbit polyclonal anti-AMOT-p80 (both Abcam,
Cambridge, UK) and mouse monoclonal anti-b-actin (Sigma
Aldrich), anti-goat IgG horseradish peroxidase (HRP; Amersham
Ltd, Amersham, UK), anti-rabbit IgG HRP (New England
Biolabs, Hitchin, UK) and anti-mouse IgG HRP (Cell Signalling,
Hitchin, UK).
Western blotting. Cell pellets were lysed using RIPA buffer
(Sigma Aldrich) containing protease and phosphatase inhibitors
(Roche, West Sussex, UK) and extracted proteins quantified using
the BCA method (Smith et al, 1985). Protein extracts (100 mg) were
loaded onto 12% (v/v) SDS-PAGE, followed by wet transfer to
nitrocellulose. Following incubation in blocking buffer (5% milk
and 3% BSA in TBS containing 0.05% Tween-20) for 1 h
membranes were incubated overnight at 4 1C with anti-HOXD10
(1 : 250) or AMOT-p80 (1 : 250) antibodies. Membranes were
incubated in anti-goat IgG HRP (1 : 50 000) or anti-rabbit IgG HRP
(1 : 3000) antibodies for 1 h at room temperature and developed
with SuperSignal west pico chemiluminescent substrate (Fisher
Scientific).
Immunohistochemistry (IHC). HOXD10 protein expression was
assessed in a tissue microarray containing normal oral mucosa,
OPL, primary HNSCC and metastases. AMOT-p80 expression was
assessed in a smaller subpanel of normal and HNSCC tissues.
Microwave or pressure cooker antigen retrieval was used and
samples were incubated with the primary antibody, rabbit anti-
HOXD10 (1 : 50) or rabbit anti-AMOT-p80 (1 : 50), overnight at
4 1C. Vectastain Elite ABC Rabbit IgG kit (Vector Ltd, Peter-
borough, UK) was used for the secondary antibody step followed
by colour development using DAB. Specificity of the antibody was
assessed by pre-adsorption with the immunogenic peptide
(Abcam). Staining was assessed using the Quickscore method
(Detre et al, 1995).
HOXD10 and AMOT-p80 plasmid construction. Primers ampli-
fying the coding regions of HOXD10 and AMOT-p80 included a
CACC sequence to aid the insertion into pcDNA3.1-TOPO
mammalian expressing vector (Life Technologies); HOXD10
forward: 50-CACCATGTCCTTTCCCAACAGCT-30, reverse:
50-CTAAGAAAACGTGAGGTTGGCGG-30, AMOT-p80 forward:
50-CACCATGCCTCGGGCTCAGCCATCCTC-3’, reverse: 50- TTAG
ATGAGATATTCCACCATCTCTGCATCAGGCTCTTGTC-30.
Successful cloning of target sequences was confirmed by
sequencing.
Plasmid, shRNA and siRNA transfection. Cells were transfected
in six-well plates with pcDNA3.1-control, pcDNA3.1-HOXD10,
pcDNA3.1-AMOT, control shRNA or HOXD10 shRNA plasmids
DNA (1 mg per well) using FuGENE HD (Promega, Southampton,
UK), whereas HOXD10 siRNA (OriGene, Rockville, MD, USA)
transfection was carried out at 50 nM final concentration with
Oligofectamine (Invitrogen, Loughborough, UK), as per the
manufacturer’s protocol. Following transfection, cells were incu-
bated for 48–72 h in their normal media before use in phenotypic
or gene expression analyses. Stably transfected cells were selected
using G418 (400 mgml 1; Fisher Scientific) in a 12-well plate for
2 weeks. Selected colonies were expanded and cells were grown in
antibiotic-containing media to maintain selection pressure. Trans-
fection efficiency was confirmed using qPCR and western blotting.
Proliferation and apoptosis assays. Cells were seeded (4000 cells
per well) in a 96-well plate in triplicate for each time point in
DMEM supplemented with 10% (v/v) FCS. At each time point,
wells were washed with PBS before adding 100 ml serum-free
DMEM medium and MTS reagent (Promega). Absorbance was
read at 490 nm using a microplate spectrophotometer (Tecan Ltd,
Theale, UK).
Apoptotic cells were quantified using the TACS Annexin
V-FITC Apoptosis Detection Kit (R&D systems, Abingdon, UK).
Cells were cultured in tissue culture flasks in their respective
medium until they are 80% confluent, trypsinised and 5 105 cells
transferred to a microtube. Cells were washed in ice-cold PBS
containing 0.1% BSA, resuspended in binding buffer and incubated
with Annexin V-FITC and propidium iodide according to the
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manufacturer’s instructions. Cells were analysed using a LSR II
flow cytometer (BD Biosciences, San Jose, CA, USA).
Adhesion assay. A 96-well plate was coated with 0.1% (w/v)
fibronectin (Sigma Aldrich) diluted in PBS and kept overnight at
4 1C. On the following day, wells were washed with PBS and
incubated with DMEM containing 1% (w/v) BSA for 1 h. Cells
(30 000 cells per well) were seeded in serum-free DMEM medium
and incubated for 1 h at 37 1C. Non-adherent cells were removed
by washing with PBS before adding 100 ml serum-free DMEM
medium and MTS reagent, and absorbance was measured as
described.
Transwell migration and invasion assays. To assess migration,
60 000 cells, serum-starved for 24 h, resuspended in DMEM with
0.1% (w/v) BSA and placed in the top chamber of a 24-well
Transwell insert (8 mM: BD Biosciences, Oxford, UK). DMEM was
added to the bottom well with 2% (v/v) FCS and incubated
overnight at 37 1C for 16 h. Migrated cells were stained with crystal
violet and counted. To assess cell invasion, a similar protocol was
followed with prior coating of the membrane with 100 ml of growth
factor-reduced Matrigel (BD Biosciences) diluted in PBS (1 : 45).
Mitomycin C was used at a concentration of 1 mgml 1 at both the
cell suspension and at the chemoattractant-containing medium in
the lower chamber to stop any cell division during the assay.
Agilent microarray. Total RNA was extracted from triplicate
cultures of B22 and D19 cells stably transfected with either
pcDNA3.1-HOXD10 or pcDNA3.1-control, and T5 and D35 cells
transfected with either HOXD10 siRNA or scrambled siRNA
control. RNA quality was assessed using an Agilent Bioanalyser
(28 s:18 sX2 : 1 and RIN¼ 10). Sample labelling was carried out as
per the manufacturer’s protocol before hybridisation onto
SurePrintG3 Human Oligo arrays (Agilent, Santa Clara, CA,
USA). After 17 h, hybridised slides scanned at 3-mm resolution
using Agilent C Microarray Scanner. Data were loaded into
Genespring (version 12.5), normalised by the Quartile method and
analysed using one-way ANOVA (Welch) with Benjamini–
Hochberg correction to identify significantly differentially
expressed genes with a fold change 42.
The list of significantly differentially expressed genes was
filtered using criteria to enrich for putative targets of HOXD10.
First, genes that showed reciprocal changes in expression with
HOXD10 overexpression and knockdown were selected. Next, the
promoter regions of the remaining genes were detected and
screened for HOXD10-binding sites using PROMO online
algorithm (Messeguer et al, 2002) (http://alggen.lsi.upc.es/cgi-bin/
promo_v3/promo/promoinit.cgi?dirDB=TF_8.3). Last, the overall
pattern of expression was assessed and compared with HOXD10
expression in a cell panel.
Cloning of wild-type and mutated AMOT-p80 and miR-146a
promoters. The putative promoter regions of AMOT-p80 and
miR-146a were identified using in silico analysis using http://
rulai.cshl.edu/cgi-bin/CSHLmpd2/promExtract.pl?species=Human
(Zhang, 2003), http://biowulf.bu.edu/zlab/PromoSer/ (Halees et al,
2003) and http://www.genomatix.de/solutions/genomatix-software-
suite.html (Cartharius et al, 2005). To clone the promoter sequences
into pGL3-basic luciferase reporter vector, sequences of XhoI and
HindIII restriction sites were added to forward and reverse primers,
respectively (restriction sites underlined): AMOT-p80 promoter
forward: 50-TGCTAACTCTCGAGAGTCAACTTCATATCCACC
CCCAAAA-30, reverse: 50-TACGCCAAGCTTACGACCAAGTT
CATGCCACCAT-30, miR-146a promoter forward: 50-AAAA
TTCTCGAGTTGAAAAGCCAACAGGCTCATTGG-30, reverse:
50-CAAATTTAAGCTTCCACTCCAATCGGCCCTGCT-30.
HOXD10-binding sites in AMOT-p80 and miR-146a were
predicted using PROMO algorithm: http://alggen.lsi.upc.es/
cgi-bin/promo_v3/promo/promoinit.cgi?dirDB=TF_8.3 (Messeguer
et al, 2002). Using the mutagenic PCR method, random
nucleotides in the binding site were substituted with different
nucleotides to impair HOXD10 binding. pGL3-AMOT and pGL3-
miR-146a wild-type (WT) sequence was used as the templates in
this PCR. The primers used for mutation of the HOXD10-binding
site in addition to the cloning forward and reverse primers were as
follows: (mutated bases in bold): AMOT-p80 mutagenic forward:
50-CACAATAGCCTCTTGTTTAGTCCTATTAATTTTGAGGGC
GGGTGG-30, reverse: 50-CCACCCGCCCTCAAAATTAATA
GGACTAAACAAGAGGCTATTGTG-30, miR-146a mutagenic
forward: 50-AGGGTGTGGAAATGGAATATTTGCATATGCAA
ATAGGCCTT-30, reverse: 50-AAGGCCTATTTGCATATGCAAA
TATTCCATTTCCACACCCT-30. Successful cloning was confirmed
by sequencing.
Dual luciferase reporter (DLR) assay. Cloned pGL3-AMOT and
pGL3-miR-146a wild-type (WT) and mutated promoters were
transfected using FuGENE HD (Promega) into cells stably
expressing pcDNA3.1-HOXD10 DNA or pcDNA3.1-control. To
confirm transfection efficacy and to normalise the firefly luciferase
expression, constructs were co-transfected with a pRL-TK Renilla
internal control vector in a ratio of 1 : 10. Forty-eight hours post
transfection, cells were lysed and expression levels of firefly and
Renilla luciferase were determined using the DLR assay kit
(Promega) and a GloMax luminometer (Promega) as per the
manufacturer’s instructions.
Statistical analysis. Non-parametric Kruskal–Wallis test was
performed on the IHC scoring for HOXD10 in SPSS (IBM, New
York, NY, USA). One-way ANOVA (Welch) was used to identify
differentially expressed genes in the microarray data using
Benjamini–Hochberg correction. Otherwise, Student’s t-test was
used, unless otherwise stated. Differences were considered
statistically significant if Pp0.05.
Ethics. Ethics approval for the use of tissues was obtained from
The West Glasgow LREC (08/S0709/70). Ethical approval for the
NOK primary cultures used was obtained from Sheffield LREC
(09/H1308/66).
RESULTS
HOXD10 expression in HNSCC. Validation of the initial
microarray data using qPCR and WB demonstrated high HOXD10
expression in cells from primary HNSCCs compared with NOKs;
however, this elevated expression was not observed in cell cultures
from lymph node metastases, B22 and TR146 (Figure 1A and
Supplementary Figure S1). Expression in the cultures from OPLs
was variable, although some – for example, D35 – did express
HOXD10 at high levels. No clear relationship between the static
level of expression of HOXD10 and that of known interacting
molecules, such as miR-7, miR-10b and IGFBP3, was seen
(Supplementary Figure S2).
In tissues, HOXD10 was expressed in the nucleus and the
cytoplasm. This is similar to reports of a number of other HOX
genes (Abe et al, 2006) and may represent shuttling between the
nucleus and the cytoplasm (Ziegler and Ghosh, 2005). Analysis
of HOXD10 expression in a tissue microarray (TMA) from
different phases of HNSCC development demonstrated increased
expression of HOXD10 in primary tumours and loss of
expression in metastases, similar to expression changes observed
in vitro (Figure 1B and C). The OPL tissues (with a range of
grades of dysplasia) demonstrate an intermediate pattern of
HOXD10 expression, which is variable. Further analysis
in TMA constructed from a cohort of 27 matched HNSCC
primary tumours and metastases confirmed the pattern with
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Figure 1. HOXD10 expression in a panel of normal, OPL and HNSCC cells and in HNSCC tissues. (A) HOXD10 expression in a panel of normal
oral keratinocytes, oral premalignant lesion and HNSCC cell lines, assessed using qPCR. HOXD10 expression is high in primary HNSCC, low in
HNSCC metastases and variable in OPLs. Each assay was conducted in triplicate and repeated three times. The data show the mean of triplicate
repeats±s.e.m. (B) Examples of expression of HOXD10 as assessed using IHC in normal, OPL and HNSCC tissues (from the cohort in C),
demonstrating high expression in primary HNSCC. 1 is normal oral mucosa; 2 is OPL; 3 is primary HNSCC; and 4 is metastatic HNSCC.
Photomicrograph overall magnification  200, scale bar¼200mm. (C) Overall IHC Quickscore of HOXD10 expression in the full cohort of tissues
from normal mucosa (n¼30), OPL (n¼18), primary HNSCC (n¼ 82) and HNSCC metastases (n¼ 27). ***Po0.001. (D) Mean Quickscore of
HOXD10 expression assessed by IHC in a panel of 27 matched primary HNSCC with matched metastases. Expression of HOXD10 is lower in the
metastasis in 23 out of 27 (85%) cases (Po0.05).
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expression lower in the metastases of 23 out of 27 patients
(85%; Figure 1D).
Effects of manipulation of HOXD10 expression. First, we
assessed the phenotypic consequences of transfecting HOXD10
into low-HOXD10-expressing OPL and metastatic HNSCC cells.
Stable overexpression of HOXD10 was achieved in two cell lines,
D19 (OPL) and B22 (metastasis), and confirmed using both qPCR
and western blot analyses (Figure 2A). Increasing the expression of
HOXD10 resulted in an increase in migration, adhesion to
fibronectin and cell proliferation (Figure 2B–D) but a decrease in
cell invasion (Figure 2E). The proportion of apoptotic cells in D19
was unchanged; however, a small increase was seen in B22
(Supplementary Figure S3A and B). Conversely, knockdown of
HOXD10 was achieved using siRNA and confirmed using qPCR in
high-HOXD10-expressing D35 (OPL) and T5 (HNSCC) cells
(Figure 3A). This resulted in a decrease in migration, adhesion to
fibronectin and proliferation, and an increase in invasion
(Figure 3B–E), eliciting opposite effects to those seen on HOXD10
overexpression. There was no change in the proportion of
apoptotic cells (Supplementary Figure S3C and D).
Microarray analysis of transfected cells. To identify the pathways
and individual genes through which HOXD10 exerts these effects,
we conducted expression microarray analysis of cells with stable
HOXD10 overexpression (D19þ and B22þ ) or knockdown
(D35 and T5 ). After normalisation, data analysis yielded 9167
genes whose expression was significantly reciprocally altered in
HOXD10-overexpressing and siRNA-transfected cells. The list was
refined to 414 genes, using an overall fold change of 42. Gene
ontology (GO) mapping of the differentially expressed genes
identified a number of significantly enriched GO categories
(Supplementary Table S1). These map to the effects seen in the
cells on the manipulation of HOXD10.
Validation of putative HOXD10 target genes. After further
filtering by in silico analysis, a final list of 48 differentially
expressed genes were identified as putative targets of HOXD10
(Figure 4A; Supplementary Table S2). Using qPCR analysis, the
expression level of the selected 48 HOXD10 putative targets were
assessed in the manipulated cells and also in the whole panel of cell
lines (data not shown). Thirty-nine of these genes showed a
negative or positive correlation between their expression and
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HOXD10 expression in both HOXD10-manipulated cells and a
panel of cell lines. The top eight differentially expressed genes are
shown in Figure 4B, selected on the basis of close relation to
HOXD10 expression and in silico analysis for putative HOXD10-
binding sites in the promoter; the two candidates that most closely
matched HOXD10 expression were angiomotin (transcript variant
2, AMOT-p80) and miR-146a.
Immunoblotting showed that AMOT-p80 protein expression
increased after HOXD10 transfection in low expressing OPM and
HNSCC cells (Figure 5A) but was reduced in high-expressing (D35
and T5) cells transfected with HOXD10 siRNA (Figure 5B), in
keeping with the microRNA data. AMOT-p80 expression was also
assessed in a wider panel of NOKs, OPL and HNSCC cells,
showing a pattern of expression that is similar to that of HOXD10
(Supplementary Figure S5C and D). miR-146a expression
decreased after HOXD10 transfection in low expressing OPL and
HNSCC cells (Figure 5C) and was induced after HOXD10 siRNA
transfection into high-expressing cells (Figure 5D). miR-146a
expression was also assessed in the same panel of NOKs, OPL and
HNSCC cells, showing high expression in normal cells, and low
expression in HNSCC cells, which suggests a negative correlation
with HOXD10 expression level (Supplementary Figure S5A and B).
Investigation of AMOT-p80 and miR-146a promoters as direct
targets of HOXD10. HOXD10 overexpression increased lucifer-
ase activity from a wild-type AMOT-p80 promoter reporter
construct (Figure 5E). This was not observed after mutation of
the putative HOXD10-binding sites in the promoter (Figure 5E),
indicating a direct effect of HOXD10 on AMOT-p80 expression at
a transcriptional level. The effect was further increased by mutating
more than one HOXD10-binding site. HOXD10 overexpression
suppressed luciferase activity from a wild-type miR-146 promoter
reporter construct (Figure 5F). This was not observed after
mutation of the putative HOXD10-binding site (Figure 5F),
indicating that HOXD10 directly suppresses miR-146a expression
by interacting with its promoter.
The function of AMOT-p80 in HNSCC cells. Transient transfection
of AMOT-p80 into HNSCC cells that express low levels of HOXD10
and AMOT (B22 and D19, expression confirmed using qPCR and
WB in Figure 6A) resulted in similar phenotypic changes to
transfection with HOXD10; there was an increase in proliferation
and migration of cells (Figure 6B and C). There was no effect on
adhesion to fibronectin (Figure 6D).
Transfection of AMOT-p80 into cells stably depleted of
HOXD10 (Figure 7A) rescued the phenotype, with partial reversal
of the reduction in proliferation (Figure 7B) and reversion of
migration to a level higher than original control levels (Figure 7C).
Assessment of expression of AMOT-p80 in a panel of normal
oral mucosa and HNSCC tissues showed that the expression of
AMOT-p80 was much higher in the HNSCC samples, where there
was both cytoplasmic and nuclear expression of AMOT-p80
(in keeping with a recent report in hepatocellular tumorigenesis
(Yi et al, 2013)) with focal light cytoplasmic expression in normal
oral mucosa (Figure 7D).
DISCUSSION
Various HOX genes have been described to have a role in the
development of a wide range of cancers. The role of HOXA cluster
genes in haematolymphoid cancers has been extensively investi-
gated, resulting in the identification of a number of fusion proteins
(for example, NUP98 :HOXC11) that results in aberrant HOX
trans-regulatory activity. In primary breast cancers, HOXA5,
HOXA9 and HOXB13 are downregulated, whereas HOXB9 and
HOXD10 are upregulated (Chen et al, 2004; Ma et al, 2007; Gilbert
et al, 2010). Changes in the expression of other HOX genes have
been reported in lung and gastric cancers (Abe et al, 2006).
In HNSCC, several HOX genes, including HOXA5, HOXD10 and
HOXD11, show higher levels of expression in oral cancer tissues
compared with normal tissues (Rodini et al, 2012). Although high
expression levels of HOXD10 have previously been observed in
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invasive oral cancers, this is the first study to explore the functional
roles of HOXD10 in HNSCC development. We also demonstrate
that HOXD10 expression is reduced in HNSCC metastases relative
to their paired primary tumours.
We show that HOXD10 promotes the proliferation, migration
and adhesion to fibronectin of primary HNSCC cells, with no
consistent effect on apoptosis, by demonstrating reciprocal
phenotypic changes on overexpression of knockdown of HOXD10.
These effects may promote the development of the primary tumour
as it becomes established at the primary site. This is supported by
the observation that some OPL cells also express high levels of
HOXD10. Thus, it is likely that increasing HOXD10 expression
during HNSCC development supports the emergence of cells that
populate the primary tumour. Interestingly, the observations that
HOXD10 suppresses invasion into matrigel, that expression of
HOXD10 is low in cells derived from metastases and that the
tumour loses expression of HOXD10 in its metastases suggest a
change in the role HOXD10 is having as cancer develops and
spreads to sites distant to the primary tumour. Inhibition of
invasion by HOXD10 would indicate antimetastatic properties,
which have been demonstrated in other cancer types (Ma et al,
2010). The overall pattern of high primary tumour HOXD10
expression, with the loss of expression in metastases that we have
observed, has been reported in other cancer types, such as bladder
cancer (Baffa et al, 2009). Furthermore, in breast cancer,
tumorigenic but nonmetastatic breast cancer cell lines express
little or no miR-10b, which downregulates HOXD10 expression, in
keeping with high HOXD10 expression (Ma et al, 2007). However,
this does not seem to be a consistent pattern across all cancer types,
as in primary gastric cancer types HOXD10 is downregulated by
promoter methylation, which profoundly inhibits proliferation
and migration (Wang et al, 2012). This highlights the context
and cell-specific roles of these transcription factors, particularly as
their expression may be regulated by a number of different
mechanisms.
In breast and gastric cancer cells, high expression of miR-10b
activates signalling via the RhoC-AKT signalling pathway that
promotes migration and invasion (Ma et al, 2007; Liu et al, 2012).
Our phenotypic assessment of the effects of HOXD10 in HNSCC
cells indicates that low expression of HOXD10 is associated with
increased invasive potential and the expression microarray analysis
of these cells indicates that low HOXD10 expression increases the
expression of a number of known modulators of epithelial–
mesenchymal transition (EMT; Supplementary Figure S4 and
Supplementary Table S2). Indeed, recent investigations in stem cell
programming and cancer have demonstrated that miR-10b (and
other microRNAs) modulates EMT (Han et al, 2014), which is also
known to be an important part of the pro-metastatic phenotype
cancer cells derive as they develop. The direct link to HOXD10,
however, has not been made in this context.
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The mechanism of downregulation of HOXD10 in HNSCC as it
metastasises is not clear. In contrast to that seen in breast
and ovarian cancer, there is no direct relationship between
the expression of HOXD10 and miR-10b in HNSCC,
(Supplementary Figure S2), in keeping with other work in the
field (Severino et al, 2013). Our unpublished observations also
suggest that downregulation is not due to promoter methylation in
these HNSCC cells (data not shown). Thus, there is scope for
further investigation of other potential mechanisms of modulation
of HOXD10 in keratinocytes, both in terms of the initiating
promotion of expression and its subsequent loss in lymph node
metastases. Other suggestions include the possible role of long
non-coding RNAs such as HOTAIR; however, these effects also
appear to be tumour-specific (Nakayama et al, 2013).
The differential pattern of expression observed here poses
interesting questions regarding the possible uses of HOXD10 both
as a biomarker and as a potential therapeutic target. Of the
tumours that metastasised, all demonstrated the pattern of high
expression in the primary tumour and low expression in
metastases. No significant association of the loss of HOXD10
expression in the primary tumour with the presence of metastasis
was identified; thus, it is unlikely to be useful as a prognostic
biomarker. Similarly, it is not likely to be a potential therapeutic
target in itself, as both high and low expression, in the correct
context, can support development and progression of the tumour.
Nevertheless, its possible utility as a marker of progression of OPLs
to HNSCC warrants further investigation, given the high
expression in some OPL cells and tissues that may be related to
the risk of progression to invasive disease. In addition, as HOXD10
is acting as a transcription factor, identification of the targets of
HOXD10 at the particular stage of disease development indicated
may identify useful biomarkers or novel therapeutic targets.
We used expression microarray analysis to identify possible
targets of HOXD10. Although this approach has acknowledged
limitations, our algorithm for target identification was successful in
the identification of a number of novel direct HOXD10 targets,
including angiomotin (AMOT-p80) and miR-146a.
miR-146a is well established as an inhibitor of cell proliferation
and as a suppressor of metastasis (Hurst et al, 2009; Chen et al,
2013; Yao et al, 2013), and thus the finding that HOXD10
decreases miR-146a expression is in keeping with the observed
phenotype. We therefore conducted detailed investigation on the
role of the novel identified target, AMOT-p80, understanding of
which in the context of cancer biology is limited.
The angiomotin family of proteins, in which there are three
members (AMOT, AMOTL1 and AMOTL2), belongs to the motin
family of angiostatin-binding proteins and is involved in the
regulation of cell growth and motility. They have been localised in
close association with tight junctions, whose enhanced turnover
has been associated with promotion of tumour development in
HNSCC (Vilen et al, 2012). Two isoforms of AMOT have been
identified (p80 and p130), with the increased expression of
AMOT-p80 associated with increased migration of endothelial
cells (Ernkvist et al, 2008). The activity of AMOT-p80 is inhibited
by the 4.1 protein superfamily member, Merlin, in a complex at
tight junctions which includes YAP, LATS and other AMOT
family members (Paramasivam et al, 2011). Recent investigations
have demonstrated that AMOT-p80 opposes the activation of
signalling pathways by other AMOT family members, including
activation of tumour suppressors YAP and LATS2 (Zhao et al,
2011). Others have shown that AMOT-p80 promotes tumour
growth in a number of different contexts: signalling via RAS-
MAPK to promote both proliferation of embyronal kidney cell
lines and enhanced development of xenograft tumours in mice
using NF2 null Schwann cells (Yi et al, 2011); signalling via ERK1/
2 in breast cancer cells, resulting in increased proliferation and
dysregulated cell polarity that resulted in a more neoplastic growth
pattern (Ranahan et al, 2011). Our data in HNSCC support the role
of AMOT-p80 in the promotion of tumour growth, although it is
not clear whether HOXD10 has a role in control of AMOT-p80
expression in these other tumour types. Nevertheless, AMOT-p80
is a potential target for novel therapeutics that may be useful in a
number of cancer types. Both AMOT-p80 and miR-146a,
identified here as novel HOXD10 targets, may represent ther-
apeutic targets at particular tumour-promoting stages.
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